Batu Biologics Appoints Alan Lewis to Chairman of the Board

Batu Biologics Appoints Biopharmaceutical Executive Dr. Alan Lewis as Chairman of the Board

World Class Industry Expert to Accelerate Development of Cancer Immunotherapeutic Platform after IND Filing for Lung Cancer Indication

Batu Biologics, a San Diego biotechnology company dedicated towards the development of its cancer angiogenesis-targeting immunotherapeutic product, ValloVax, announced today the appointment of Dr. Alan Lewis as Chairman of the Board of Directors.

Read the full article at businesswire.com

Startup applies to test cancer therapy

Batu Biologics, a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of new blood vessels that feed tumors.

The San Diego startup said Thursday that its therapy, ValloVax™, will be tested in a Phase 1/2 trial against non-small cell lung cancer once the U.S. Food and Drug Administration approves the application.

ValloVax™ targets proteins found in blood vessels induced by cancer that are not present in ordinary blood vessels. In mouse models, the vaccine inhibited tumor formation in melanoma, breast and lung cancer.

UCSD brain cancer specialist Dr. Santosh Kesari said he’s asked Batu if he can take part in the clinical trial.

“The innovative thing about this technology is that you’re combining two powerful, validated technologies in one: angiogenesis inhibitors and immunotherapy,” Kesari said. “I think it has a lot of potential.”

Read the full article as posted by U-T San Diego here

Bringing Innovative Weapons To the Cancer Battlefront

What if we could engineer “killer cells” to wage war on tumors, and then program the little soldiers to seek a specific kill zone? What if glowing tumors could tell doctors which tissue material to remove during surgery?

These are just two of the recent breakthroughs in cancer research being undertaken by the hundreds of local bio- tech firms that are pumping money and resources into the oncology market — a market that’s booming with players, inno- vations and a demand that just won’t quit.

San Diego-based Batu Biologics Inc., is taking a more inventive approach. Batu’s new cancer vaccine, ValloVax™, is designed to target and kill blood vessels that feed tumor growth. In doing so, Batu expects white blood cells to invade the tumor site and encourage immune-based remission. Without being able to form new blood vessels, a tumor cannot grow bigger than 1 millimeter, said 22-year-old CEO Samuel Wagner.

Wagner said the company is set to file an investigational new drug application with the U.S. Food and Drug Admin- istration in the first quarter of 2015, and hopes to begin clinical trials after approval. Batu recently signed a license agreement with the Regents of the University of California granting Batu exclusive rights to develop and commercialize their HMGB-1 derived vaccine platform, a technology that can be used in conjunction with ValloVax™ to “supercharge” the potency of the immune response.

Download the full article as seen in the San Diego Business Journal here

Startup Conducts Unusual Funding ‘Experiment’

A local biotech startup and its 22 year old CEO — with support of local industry veterans — are trying a no-strings-attached funding model to finance their research on a potential cancer vaccine.

“If we raise money at this point in the preclinical stages, the venture capitalists or investors are going to take a large portion of our shares,” President and CEO Samuel Wagner said. “If we want to have the biggest payout for the founders, it’s really in our benefit to raise the least amount of capital in the early stages of the company.”

Batu’s new cancer vaccine is designed to target and kill blood vessels that feed tumor growth. In doing so, Batu expects white blood cells to invade the tumor site and encourage immune-based remission. Without being able to form new blood vessels, a tumor cannot grow bigger than about 1 millimeter, Wagner said, adding that tumors need those blood vessels to become malignant. “Everybody has been attacking the tumor directly,” Wagner said. “We’re choosing a different approach. … We’re trying to choke it of this blood supply.”

Download the full article as seen in the San Diego Business Journal here